EAM Investors’s X4 Pharmaceuticals XFOR Stock Holding History

EAM Investors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,927	Closed	-$1.1M	–	394
2023 Q2	$1.1M	Buy	+18,927	New	+$973K	0.2%	223

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM Investors's XFOR Position: Q3 2023 in Review

EAM Investors sold out of X4 Pharmaceuticals (XFOR) in Q3 2023, closing a stake of 18,927 shares — an estimated $1.1M sold.

EAM Investors first reported a position in XFOR in Q2 2023 and held it in 1 quarter. The position peaked at $1.1M in Q2 2023. 91 funds tracked by Wall St. Rank hold XFOR as of Q3 2023.

EAM Investors reported no remaining X4 Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
EAM Investors sold 18,927 X4 Pharmaceuticals shares in Q3 2023, an estimated $1.1M.
EAM Investors first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 1 quarter.
EAM Investors's X4 Pharmaceuticals position peaked at $1.1M in Q2 2023.
91 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.